Mixed Metastatic Lung Cancer Lesions in Bone Are Inhibited by Noggin Overexpression and Rank:Fc Administration
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Lung cancer metastases to bone produce a primarily mixed osteolytic/osteoblastic lesion. The purpose of this study was to determine if blockade of both pathways would inhibit the formation these lesions in bone. Inhibition of the osteoblastic lesion with noggin and the osteolytic lesion with RANK:Fc was a successful treatment strategy to inhibit progression of mixed lung cancer lesions in bone. Introduction: Approximately 9–30% of patients with lung cancer develop bone metastases, leading to significant morbidity and mortality. A549 is a non–small-cell lung cancer (NSCLC) line that produces a mixed metastatic lesion in bone. We sought to determine if blockade of key components in both osteolytic and osteoblastic pathways would result in a reduction of a NSCLC tumor progression in a murine model of bony metastasis. Materials and Methods: The study used a retroviral vector overexpressing noggin (RN), a specific inhibitor of BMP, and RANK:Fc, a chimeric protein that inhibits the RANK–RANKL interaction. A549 cells were transduced with RN before implantation in SCID mice. Cells were implanted in a subcutaneous model and tibial injection model. RANK:Fc was administered twice weekly at 15 mg/kg. There were five treatment groups: A549; A549 + RN; A549 + RANK:Fc; A549 + empty vector; and A549 + RN + RANK:Fc (n = 10/group). Results: In SCID mice who underwent subcutaneous A549 tumor cell injection, animals treated with A549 + RN had significantly smaller subcutaneous tumor size at 8 weeks. In an intratibial model of bony metastasis, animals injected with A549 cells developed a mixed lytic/blastic lesion with cortical destruction at 8 weeks. Treatment with RANK:Fc inhibited the formation of osteoclasts, led to a smaller tumor volume in bone, and inhibited the lytic component of the mixed lesion. Animals treated with A549 + RN had a decreased number of osteoblasts in bone lesions, smaller tumor volume, and inhibition of the blastic component of the mixed lesions. Combination treatment inhibited both the lytic and blastic components of the lesion. Conclusions: The NSCLC cell line A549 forms a mixed osteolytic/osteoblastic lesion in vivo. Noggin overexpression inhibited the formation of the osteoblastic aspect of the lesion in bone and the tumor growth in vivo. Treatment with RANK:Fc limited the formation of the lytic aspect of the mixed lesion and also inhibited the rate of in vivo tumor growth. Inhibition of both pathways is necessary to effectively inhibit the progression of mixed metastatic lesions in bone.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
RANK ligand is a prerequisite for cancer-associated osteolytic lesions.
Kitazawa, S., & Kitazawa, R. (2002) · The Journal of Pathology · doi:10.1002/path.1199 · Cited by 141 · cited 1×
“necessary for the development of osteolytic lesions in bone.((18)) Furthermore, inhibition of the RANK:RANKL”
BackgroundInfluence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer
Feeley, B. T., Gamradt, S. C., Hsu, W. K., Liu, N., Krenek, L., Robbins, P., Huard, J., & Lieberman, J. R. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.050802 · Cited by 120 · cited 6×
“We have previously shown that BMP-2 is a potent stimulator of migration and invasion of osteolytic and osteoblastic prostate cancer cells.((4,6)) In those studies, overexpression of noggin was associated with a decrease in the size of the osteolytic prostate cancer tumors in bone and a decrease in the formation of ost…”
BackgroundResultInfluentialSelf-citation
Cited by
Bench to bedside: elucidation of the OPG–RANK–RANKL pathway and the development of denosumab
Lacey, D. L., Boyle, W. J., Simonet, W. S., Kostenuik, P. J., Dougall, W. C., Sullivan, J. K., Martin, J. S., & Dansey, R. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3705 · Cited by 694
Self-citationProgression and metastasis of lung cancer
Popper, H. H. (2016) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9618-0 · Cited by 545
McLean, K., Gong, Y., Choi, Y., Deng, N., Yang, K., Bai, S., Cabrera, L., Keller, E., McCauley, L., Cho, K. R., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45273 · Cited by 380
Scagliotti, G. V., Hirsh, V., Siena, S., Henry, D. H., Woll, P. J., Manegold, C., Solal-Celigny, P., Rodriguez, G., Krzakowski, M., Mehta, N. D., et al. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31826aec2b · Cited by 335
Xu, Z., Li, E., Guo, Z., Yu, R., Hao, H., Xu, Y., Sun, Z., Li, X., Lyu, J., & Wang, Q. (2016) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6b08746 · Cited by 264
Metadata
- Authors
- Feeley, B. T., Liu, N. Q., Conduah, A. H., Krenek, L., Roth, K., Dougall, W. C., Huard, J., Dubinett, S., & Lieberman, J. R.
- Venue
- Journal of Bone and Mineral Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-10-01
- Volume
- 21
- Issue
- 10
- Pages
- 1571-1580
- ISSN
- 0884-0431 (ISSN-L)
- 1523-4681
- OpenAlex
- W1967615426
- Cited by
- 122
- References
- 2
- FWCI
- 3.72
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mixed Metastatic Lung Cancer Lesions in Bone Are Inhibited by Noggin Overexpression and Rank:Fc Administration. https://app.cochat.ai/papers/10.1359/jbmr.060706
- The paper
- Feeley, B. T., Liu, N. Q., Conduah, A. H., Krenek, L., Roth, K., Dougall, W. C., Huard, J., Dubinett, S., & Lieberman, J. R. (2006). Mixed Metastatic Lung Cancer Lesions in Bone Are Inhibited by Noggin Overexpression and Rank:Fc Administration. Journal of Bone and Mineral Research. https://doi.org/10.1359/jbmr.060706
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.